Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Patricia Xavier Santi"'
Autor:
Marco Colleoni, Yasuhiro Fujiwara, Vladimir Hanes, Hans Christian Kolberg, Patricia Xavier Santi, Hans Tesch, Zorica Tomasevic, Georgia Demetriou
Publikováno v:
Drug Safety
Although the human epidermal growth factor receptor 2 (HER2) blocker trastuzumab is generally well tolerated, cardiotoxicity can be an important therapeutic limitation.Objective.In this prespecified analysis, we compared the cardiac safety of the tra
Autor:
Vladimir Hanes, Hans Tesch, Hanz-Christian Kolberg, Marco Colleoni, Yasuhiro Fujiwara, Patricia Xavier Santi, Georgia Demetriou
Publikováno v:
Cancer Research. 80:OT1-03
Pathological complete response (pCR) after neoadjuvant therapy is an accepted surrogate endpoint for breast cancer registration trials and is a strong prognostic biomarker especially in high-risk tumor biology. The LILAC study, a comparative trial fo
Autor:
Abna Faustina de Sousa Vieira, Patricia Xavier Santi, Vitor Augusto Queiroz Mauad, Auro Del Giglio, Daniel de Iracema Gomes Cubero
Publikováno v:
Journal of Natural Remedies, Vol 19, Iss 1, Pp 1-11 (2019)
Background: Hot flashes are common in menopausal women and significantly affect the quality of life of many patients diagnosed with breast cancer for which hormone replacement therapy is not indicated. In a previous uncontrolled study, guarana (Paull
Autor:
Jean Henri Maselli Schoueri, Daniel de Iracema Gomes Cubero, Stéphane Tomás da Luz, Patricia Xavier Santi, Auro del Giglio, Claudia Vaz de Melo Sette
Publikováno v:
Clinical Oncology Letters. 4
Autor:
Marco Colleoni, Patricia Xavier Santi, Yasuhiro Fujiwara, Vladimir Hanes, Zorica Tomasevic, Hans Tesch, Georgia Demetriou, Hans-Christian Kolberg
Publikováno v:
Journal of Clinical Oncology. 37:557-557
557 Background: Although trastuzumab is generally well-tolerated, cardiotoxicity is the main limitation in its use, leading to a severe heart failure in 2-4% of patients in adjuvant trials. In the phase 3 LILAC trial, trastuzumab biosimilar ABP 980 d
Autor:
Livia Tiemi, Rebecca Melo Zanellato, Saulo Silva Oliveira, Auro Del Giglio, Lucas Reifur, Patricia Xavier Santi, Tatiana Goberstein Lerner, Adriana Braz del Giglio
Publikováno v:
Einstein (São Paulo), Vol 11, Iss 4, Pp 435-438
Einstein (São Paulo), Volume: 11, Issue: 4, Pages: 435-438, Published: DEC 2013
einstein (São Paulo) v.11 n.4 2013
Einstein (São Paulo)
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
Einstein (São Paulo), Volume: 11, Issue: 4, Pages: 435-438, Published: DEC 2013
einstein (São Paulo) v.11 n.4 2013
Einstein (São Paulo)
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
OBJETIVO: Avaliar se a Paullinia cupana diminui o número e a gravidade dos fogachos em mulheres após diagnóstico de câncer de mama. MÉTODOS: Estudo piloto prospectivo fase II realizado com mulheres que sobreviveram ao câncer de mama, que comple
Autor:
Vladimir Hanes, Yasuhiro Fujiwara, N Zhang, Zorica Tomasevic, Patricia Xavier Santi, Georgia Demetriou, Hans Tesch, Hans-Christian Kolberg, Marco Colleoni
Publikováno v:
Journal of Clinical Oncology. 36:583-583
583Background: The phase 3 LILAC Study compared ABP 980 with trastuzumab (TRAS) on pathologic complete response (pCR) in women with HER2+ early breast cancer. The primary efficacy results, based on...
Publikováno v:
Revista da Associação Médica Brasileira v.61 n.5 2015
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Volume: 61, Issue: 5, Pages: 411-416, Published: OCT 2015
Revista da Associação Médica Brasileira, Vol 61, Iss 5, Pp 411-416 (2015)
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Volume: 61, Issue: 5, Pages: 411-416, Published: OCT 2015
Revista da Associação Médica Brasileira, Vol 61, Iss 5, Pp 411-416 (2015)
Summary Background: to evaluate if time between surgery and the first adjuvant treatment (chemotherapy, radiotherapy or hormone therapy) in patients with breast cancer is a risk factor for lower overall survival (OS). Method: data from a five-year re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2576cd15ce94254e71dfa1b685366dc1
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411
Autor:
Viviane Lealdini, Damila Cristina Trufelli, Leandro Luongo de Matos, Savia Raquel Costa Normando, Fernando Luiz Affonso Fonseca, Auro Del Giglio, Patricia Xavier Santi, Elisa Watanabe Camargo, Fernanda Borges Ferreira da Silva
Publikováno v:
Journal of geriatric oncology. 6(6)
Objectives To evaluate the relationship between inflammatory parameters through the modified Glasgow Prognostic Score (mGPS) and other clinical characteristics of elderly patients with cancer, including frailty evaluated by the Edmonton Frailty Scale
Autor:
Damila Cristina Trufelli, Suelen Patrícia dos Santos Martins, Daniel de Iracema Gomes Cubero, Auro Del Giglio, Felipe Melo Cruz, Patricia Xavier Santi, Fernando Luiz Affonso Fonseca, Eliana Araújo da Silva, Larissa Carvalho Lopes de Paula, Fábio Ferreira Perazzo
Publikováno v:
Journal of alternative and complementary medicine (New York, N.Y.). 21(1)
Cat's claw (Uncaria tomentosa) is a native Amazon plant that exhibits anti-inflammatory and antitumor properties. We wanted to assess its activity for symptom management of terminal cancer patients.This prospective phase II study assessed the effects